Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage

被引:41
作者
Dassesse, Thibaut
de Leval, Xavier
de Leval, Laurence
Pirotte, Bernard
Castronovo, Vincent
Waltregny, David
机构
[1] Univ Liege, Metastasis Res Lab, Ctr Expt Canc Res, B-4000 Liege, Belgium
[2] Univ Liege, Med Chem Lab, Nat & Synth Drugs Res Ctr, B-4000 Liege, Belgium
[3] Univ Liege, Dept Pathol, B-4000 Liege, Belgium
[4] Univ Liege, Dept Urol, B-4000 Liege, Belgium
关键词
prostate; cancer; cyclooxygenase; thromboxane; prognosis;
D O I
10.1016/j.eururo.2006.01.036
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objective: We investigated the potential involvement of the thromboxane A(2) (TXA(2)) pathway in human prostate cancer (PCa). Methods: Expression of cyclooxygenase-2 (COX-2), TXA2 synthase (TXS), and TXA(2) receptors (TPRs), the main actors of the TXA2 pathway, was analyzed on serial tissue sections from 46 human PCa specimens. Results: The expression levels of COX-2, TXS, and TPRs were significantly higher in malignant than in corresponding nontumoral prostatic epithelial cells. Increased immunoreactivity for these antigens was also observed in high-grade prostate intraepithelial neoplasia (HGPIN) glands. COX-2, TXS, and TPR proteins usually displayed a coordinated overexpression pattern in PCa lesions, as assessed in serial tissue sections. Increased levels of these proteins in the tumors were all significantly associated with higher Gleason scores and pathologic stages. Conclusions: Proteins specifically involved in the TXA2 pathway are up-regulated in human PCa and their level of expression is associated with tumor extraprostatic extension and loss of differentiation. our study is the first to examine simultaneously all key proteins involved in this pathway including TXA2 receptors and results suggest that the TXA2 pathway may be a potential target for PCa prevention/therapy. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1021 / 1031
页数:11
相关论文
共 64 条
[1]
Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region [J].
Arisato, T ;
Hashiguchi, T ;
Sarker, KP ;
Arimura, K ;
Asano, M ;
MAtsuo, K ;
Osame, M ;
Maruyama, I .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (12) :2589-2593
[2]
Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing [J].
Atkinson, S ;
Fox, SB .
JOURNAL OF PATHOLOGY, 2004, 203 (02) :721-728
[3]
Do selective cyclo-oxygenase-2 inhibitors have a future? [J].
Bannwarth, B .
DRUG SAFETY, 2005, 28 (03) :183-189
[4]
Evaluating radical prostatectomy specimens: Therapeutic and prognostic importance [J].
Bostwick, DG ;
Montironi, R .
VIRCHOWS ARCHIV, 1997, 430 (01) :1-16
[5]
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[6]
Prostanoid receptors: Subtypes and signaling [J].
Breyer, RM ;
Bagdassarian, CK ;
Myers, SA ;
Breyer, MD .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :661-690
[7]
Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness [J].
Chaplet, M ;
Waltregny, D ;
Detry, C ;
Fisher, LW ;
Castronovo, V ;
Bellahcène, A .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (04) :850-856
[8]
Daniel TO, 1999, CANCER RES, V59, P4574
[9]
Pathological and molecular aspects of prostate cancer [J].
DeMarzo, AM ;
Nelson, WG ;
Isaacs, WB ;
Epstein, JI .
LANCET, 2003, 361 (9361) :955-964
[10]
Prevalent mutations in prostate cancer [J].
Dong, JT .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 97 (03) :433-447